OrthoPediatrics (KIDS) announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis, EOS. This represents the company’s 80th system designed to treat musculoskeletal issues in children.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics: Strategic Niche and Growth Potential Justify Buy Rating
- OrthoPediatrics initiated with a Buy at Lake Street
- OrthoPediatrics: Strong Market Position and Growth Potential Justify Buy Rating with $50 Price Target
- Orthopediatrics Corp Faces Financial Uncertainty Amidst Trade and Regulatory Challenges
- OrthoPediatrics Corp’s Earnings Call Highlights Growth and Record Impact
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue